Akebia Therapeutics Inc. (AKBA) 21.44 $AKBA
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors
Business Wire - Thu Jul 17, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments.
Akebia Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global Indexes
Business Wire - Mon Jun 30, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, today announced that it was added to the Russell 3000(R),Russell 2000(R), and Russell Global Indexes when the Russell Investment Group reconstituted its family of U.S. indexes after the stock market close on June 27, 2014.
Akebia Therapeutics Announces Upcoming Presentation at 51st ERA-EDTA Annual Congress
Business Wire - Thu May 29, 6:01AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, today announced that data on its lead clinical compound, AKB-6548, will be presented at the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51st Congress being held in Amsterdam May 31 - June 3, 2014. AKB-6548 is a once-daily, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor in development for the treatment of anemia related to chronic kidney disease (CKD).
Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Mar 26, 7:02AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. This includes the exercise in full by the underwriters of their option to purchase 879,647 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $106.9 million. All of the shares of common stock were offered by Akebia.
3 IPOs launched, more on Fri.
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Shares of Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for kidney disease, priced at 17 and opened at 22.90. Shares ended the day at 26.69. Q2 Holdings (QTWO), which provides online banking services, priced at 13 and...
IPO Sizzle Continues With A10 Networks Set For Friday
at Investor's Business Daily - Thu Mar 20, 1:03PM CDT
Three IPOs launched Thursday, continuing a hot streak that will carry into Friday when A10 Networks (ATEN) is set to debut. A top performer Thursday was Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for patients with...
Akebia and MediWound rise as health IPOs continue
AP - Thu Mar 20, 11:11AM CDT
NEW YORK (AP) — Drug developer Akebia Therapeutics and burn treatment maker MediWound both went public Thursday as the tide of health care IPOs continued to rise.
Akebia Therapeutics Announces Pricing of Initial Public Offering
Business Wire - Thu Mar 20, 7:01AM CDT
Akebia Therapeutics, Inc. today announced the pricing of its initial public offering of 5,882,353 shares of common stock at an initial public offering price of $17.00 per share. In addition, Akebia has granted the underwriters a 30-day over-allotment option to purchase up to an additional 879,647 shares of common stock at the initial public offering price. The shares of Akebia's common stock are expected to begin trading on the NASDAQ Global Market on March 20, 2014 under the ticker symbol "AKBA." The offering is expected to close on March 25, 2014, subject to customary closing conditions.
Paylocity IPO Pops, Maintaining New-Issue Enthusiasm
at Investor's Business Daily - Wed Mar 19, 11:12AM CDT
The Paylocity Holding (PCTY) IPO jumped Wednesday, setting the stage for nine more IPOs this week, as new issues remain hot. Paylocity priced at 17 on Tuesday evening, above its expected range, and opened at 31 on the Nasdaq Wednesday morning. In...
Akebia Therapeutics Files Registration Statement for Proposed Initial Public Offering
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the filing of a Registration Statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the proposed offering will be offered by Akebia Therapeutics. Akebia Therapeutics has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "AKBA". The number of shares to be offered and the price range for the offering have not yet been determined.
Akebia Therapeutics Appoints Michael Wyzga to its Board of Directors
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the appointment of Michael S. Wyzga as an independent member to the company's Board of Directors. Mr. Wyzga will serve as the Chairman of Akebia's Audit Committee.
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors
Business Wire - Thu Jul 17, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments.
Akebia Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global Indexes
Business Wire - Mon Jun 30, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, today announced that it was added to the Russell 3000(R),Russell 2000(R), and Russell Global Indexes when the Russell Investment Group reconstituted its family of U.S. indexes after the stock market close on June 27, 2014.
Akebia Therapeutics Announces Upcoming Presentation at 51st ERA-EDTA Annual Congress
Business Wire - Thu May 29, 6:01AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, today announced that data on its lead clinical compound, AKB-6548, will be presented at the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51st Congress being held in Amsterdam May 31 - June 3, 2014. AKB-6548 is a once-daily, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor in development for the treatment of anemia related to chronic kidney disease (CKD).
Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Mar 26, 7:02AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. This includes the exercise in full by the underwriters of their option to purchase 879,647 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $106.9 million. All of the shares of common stock were offered by Akebia.
3 IPOs launched, more on Fri.
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Shares of Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for kidney disease, priced at 17 and opened at 22.90. Shares ended the day at 26.69. Q2 Holdings (QTWO), which provides online banking services, priced at 13 and...
IPO Sizzle Continues With A10 Networks Set For Friday
at Investor's Business Daily - Thu Mar 20, 1:03PM CDT
Three IPOs launched Thursday, continuing a hot streak that will carry into Friday when A10 Networks (ATEN) is set to debut. A top performer Thursday was Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for patients with...
Akebia and MediWound rise as health IPOs continue
AP - Thu Mar 20, 11:11AM CDT
NEW YORK (AP) — Drug developer Akebia Therapeutics and burn treatment maker MediWound both went public Thursday as the tide of health care IPOs continued to rise.
Akebia Therapeutics Announces Pricing of Initial Public Offering
Business Wire - Thu Mar 20, 7:01AM CDT
Akebia Therapeutics, Inc. today announced the pricing of its initial public offering of 5,882,353 shares of common stock at an initial public offering price of $17.00 per share. In addition, Akebia has granted the underwriters a 30-day over-allotment option to purchase up to an additional 879,647 shares of common stock at the initial public offering price. The shares of Akebia's common stock are expected to begin trading on the NASDAQ Global Market on March 20, 2014 under the ticker symbol "AKBA." The offering is expected to close on March 25, 2014, subject to customary closing conditions.
Paylocity IPO Pops, Maintaining New-Issue Enthusiasm
at Investor's Business Daily - Wed Mar 19, 11:12AM CDT
The Paylocity Holding (PCTY) IPO jumped Wednesday, setting the stage for nine more IPOs this week, as new issues remain hot. Paylocity priced at 17 on Tuesday evening, above its expected range, and opened at 31 on the Nasdaq Wednesday morning. In...
Akebia Therapeutics Files Registration Statement for Proposed Initial Public Offering
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the filing of a Registration Statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the proposed offering will be offered by Akebia Therapeutics. Akebia Therapeutics has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "AKBA". The number of shares to be offered and the price range for the offering have not yet been determined.
Akebia Therapeutics Appoints Michael Wyzga to its Board of Directors
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the appointment of Michael S. Wyzga as an independent member to the company's Board of Directors. Mr. Wyzga will serve as the Chairman of Akebia's Audit Committee.
